Quantitative MRI for Myelofibrosis

Description

This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.

Conditions

Myelofibrosis

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.

Quantitative MRI for Myelofibrosis - MRI Parameters as Biomarkers for Analyzing Extent of Disease and Measuring Response to Treatment

Quantitative MRI for Myelofibrosis

Condition
Myelofibrosis
Intervention / Treatment

-

Contacts and Locations

Ann Arbor

University of Michigan Hospital, Ann Arbor, Michigan, United States, 48109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male /female subjects over the age of 18
  • 2. Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
  • 3. No contraindications to MRI
  • 4. Able to undergo MRI without anesthesia
  • 1. Patients with pacemakers or other implanted magnetic devices that may malfunction or move because of the strong magnetic field inside the MRI room and scanner.
  • 2. Any prior adverse event associated with MRI that is not related to injection of contrast agents or other medicines.

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Michigan,

Gary Luker, M.D., PRINCIPAL_INVESTIGATOR, University of Michigan Hospital

Study Record Dates

2026-12